Journal
PLOS GENETICS
Volume 8, Issue 4, Pages 623-639Publisher
PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pgen.1002683
Keywords
-
Categories
Funding
- National Basic Research Program of China [2011CB910900]
- National Science Foundation of China [30971568]
- China Postdoctoral Science Foundation [20060390479]
- National Institutes of Health [Ro1AI 07864]
- Ministry of Science and Technology of China [2009CB941301]
- Tsinghua-Yue-Yuen Medical Sciences Fund
Ask authors/readers for more resources
The aggregation or oligomerization of amyloid-beta (A beta) peptide is thought to be the primary causative event in pathogenesis of Alzheimer's disease (AD). Considerable in vitro evidence indicates that the aggregation/oligomerization of A beta is promoted in the presence of Zn; however, the functional role of Zn in AD pathogenesis is still not well clarified in vivo. Zn is imported into the brain mainly through the solute-linked carrier (Slc) 39 family transporters. Using a genetically tractable Drosophila model, we found that the expression of dZip1, the orthologue of human Slc39 family transporter hZip1 in Drosophila, was altered in the brains of A beta 42-expressing flies, and Zn homeostasis could be modulated by forcible dZip1 expression changes. An array of phenotypes associated with A beta expression could be modified by altering dZip1 expression. Importantly, A beta 42 fibril deposits as well as its SDS-soluble form were dramatically reduced upon dZip1 inhibition, resulting in less neurodegeneration, significantly improved cognitive performance, and prolonged lifespan of the A beta 42-transgenic lies. These findings suggest that zinc contributes significantly to the A beta pathology, and manipulation of zinc transporters in AD brains may provide a novel therapeutic strategy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available